• OBJECTIVE
    • The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia.
  • PARTICIPANTS
    • The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer.
  • EVIDENCE
    • This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence.
  • CONSENSUS PROCESS
    • One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines.
  • CONCLUSIONS
    • Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.